Short update before numbers are released at the end of the quarter. No specific numbers but, plenty to suggest they are on track and growing.

Below I have listed in point form some of the key points Blair was able to share.

-well on target for vision 27

-material update coming from Europe

-record quarter

-Canada going very well

-BIO growing at 10x the category average v others in the same market

-more shelf space rolling out in Australia

-looking to close deals in Europe over next few weeks

-looking to get into pharmacy wholesale in europe

-two new products in activated biotic range to be released taking product offer to 20 with long term goal of 25-30 maintaining a focus on quality products that help people.

-first 4 activated therapeutic products to be released - gastric?, gut, menopause and supportive weight loss product (mention that pharmacy had been asking for this to help people using weight loss drugs)

-pre approval in NZ for activated therapeutics

-working on this in Canada, UK and ireland

-late state planning for final study for B&B18 strain which, will then see it rolled out across their product range.

-expect to have first year of profit

-expect to continue profitable growth for year to come.

-strategies in place to maintain high growing.

-new funds continue to come on board and although they ask to enter via a CR they have been politely told no.

These were the key points I was able to take down. I might be slightly off on the exact words but, there was enough hints from Blair that share price aside they are on track if not ahead of their vision 27 target.